On a Friday shaped by earnings surprises and policy signals, markets rewarded those willing to take risk — from discount retailers proving their resilience to crypto stocks riding a wave of Washington's rare goodwill. Biotech swung wildly and then steadied, while artificial intelligence continued its quiet absorption of vast capital. The session was less a single story than a mosaic of human bets on the future, each one reflecting a different theory of where value lives.
Retail, Crypto Stocks Lead Market Surge as Bitcoin Rallies 20%
The White House signal gave it a narrative.
Mark
Why did the White House move on crypto policy matter so much that it moved markets?
Mimi
Because for years, crypto companies didn't know which federal agency would regulate them—the SEC, the CFTC, the OCC. That uncertainty made it hard to plan, hard to invest. The Clarity Act signals that Congress might actually settle this. Investors saw it as permission to move forward.
Mark
So the 20% bitcoin rally was really about policy, not price discovery?
Mimi
It was both. Bitcoin had momentum, but the White House signal gave it a narrative. Robinhood and Coinbase don't move 12% and 8% on price action alone. They move on the idea that the industry's future just got less murky.
Mark
Moderna went up 177% in one day, then down 24%, then up 10%. That's violent.
Mimi
That's what happens when you announce a cancer vaccine breakthrough. Wednesday was euphoria—people buying on the news. Thursday was the hangover—profit-taking by people who got in early. Friday was the reset, where new buyers came in at a lower price and thought it was still a good deal.
Mark
Why would Broadcom raise $60 billion to support Anthropic? That seems like a strange move for a semiconductor company.
Mimi
It's not really. Broadcom makes the chips that power AI. If Anthropic succeeds, demand for those chips grows. It's a bet on the infrastructure layer of AI, not just the software layer.
Mark
The retail earnings were solid but not shocking. Why did they matter?
Mimi
Because retail had been weak. BJ's and Ross beating expectations and raising guidance signals that consumer spending is still holding up. That matters for the whole economy.
Der Puls
- BJ's Wholesale and Ross Stores both outpaced Wall Street's expectations and raised their outlooks, sending shares up 4% each and signaling that budget-conscious consumers are still spending.
- Bitcoin's 20% weekly surge electrified crypto-linked stocks — Robinhood leapt 12% and Coinbase gained 8% — after the White House signaled support for legislation that could finally give the industry the regulatory clarity it has long demanded.
- Moderna's stock whipsawed across three days: a 177% explosion on breakthrough cancer vaccine data, a 24% selloff as traders cashed out, and then a 10% Friday rebound as buyers stepped back in.
- Broadcom's plan to raise over $60 billion in debt to back AI company Anthropic underscored the staggering scale of capital now flowing into artificial intelligence infrastructure.
- Not all bets paid off — OSI Systems fell nearly 10% on a significant revenue miss, and Boston Beer slid 3% after its CFO announced a departure, reminding investors that not every Friday belongs to the bulls.
On a Friday shaped by earnings surprises and policy signals, markets rewarded those willing to take risk — from discount retailers proving their resilience to crypto stocks riding a wave of Washington's rare goodwill. Biotech swung wildly and then steadied, while artificial intelligence continued its quiet absorption of vast capital. The session was less a single story than a mosaic of human bets on the future, each one reflecting a different theory of where value lives.
Friday's session split its energy between the reliable and the speculative. BJ's Wholesale surprised analysts with $1.36 per share in adjusted profit on $6.09 billion in revenue — well above expectations — and raised its full-year earnings guidance. Ross Stores echoed the performance, beating second-quarter estimates and offering stronger-than-expected third-quarter guidance. Both stocks gained over 4%, a quiet affirmation that discount retail still has room to run.
The louder story belonged to crypto. Bitcoin climbed 20% over the week after the White House gathered industry leaders and expressed support for the Clarity Act, a bill aimed at resolving the long-standing regulatory ambiguity around digital assets. The policy signal was enough to move markets: Robinhood surged 12%, Coinbase gained more than 8%, and Strategy added 6%. For an industry that has spent years navigating jurisdictional uncertainty, the gesture from Washington felt like a turning point.
Biotech provided the week's most dramatic arc. Moderna had rocketed nearly 177% on Wednesday after Merck and Moderna announced late-stage trial success for a cancer vaccine. Thursday brought a sharp reversal — nearly 24% down — as early buyers locked in gains. Friday's 10% rebound suggested the market hadn't fully written off the news. Merck edged up 2% alongside it.
In the background, Broadcom moved quietly but significantly, with reports that it planned to raise more than $60 billion in debt to support Anthropic's AI ambitions — a figure that spoke to how much capital is now chasing artificial intelligence infrastructure.
Not every name participated in the optimism. OSI Systems fell nearly 10% after revenue of $484 million fell well short of the $529 million analysts had expected. Boston Beer dropped 3% on a CFO departure. But upgrades from Citi, KeyBanc, and Baird lifted O-I Glass, InnovAge, and Parsons respectively, offering quieter reminders that conviction, when well-placed, still moves stocks.
Friday's market session belonged to the retailers and the risk-takers. BJ's Wholesale opened the day with a 4% gain after delivering earnings that caught analysts off guard. The company posted $1.36 per share in adjusted profit on $6.09 billion in revenue—both figures outpacing what Wall Street had penciled in. Analysts had expected $1.17 per share on $5.97 billion. The company's confidence showed in its forward guidance: management raised its full-year earnings outlook to a range of $4.60 to $4.80 per share, up from the previous $4.40 to $4.60 band. Ross Stores followed a similar script, with shares climbing over 4% after the retailer beat second-quarter expectations and offered third-quarter guidance that also exceeded the Street's estimates.
The real momentum, though, belonged to cryptocurrency and the stocks that ride its waves. Bitcoin climbed 20% over the course of the week, propelled by an unexpected tailwind from Washington. The White House had convened crypto industry leaders and signaled support for the Clarity Act, legislation designed to establish clearer federal oversight of digital assets and settle the jurisdictional questions that have long muddied the regulatory landscape. Robinhood, the retail trading platform with deep roots in crypto, surged 12%. Coinbase, the largest U.S. cryptocurrency exchange, gained more than 8%. Strategy added 6%. The policy signal mattered because it suggested the industry might finally get the regulatory clarity it has been seeking for years.
Biotech had its own drama. Moderna's stock popped more than 10% on Friday, a rebound after a volatile two days. The company had rocketed nearly 177% on Wednesday after Merck and Moderna announced positive late-stage trial results for a cancer vaccine—the kind of news that can reshape a company's trajectory. But Thursday brought profit-taking: investors who had ridden the Wednesday surge locked in gains and sold, pushing the stock down almost 24%. Friday's bounce suggested some buyers saw the pullback as an opportunity. Merck, the partner in the vaccine development, traded up 2%.
Elsewhere, the semiconductor world was moving capital around. Broadcom shares edged up nearly 1% after Bloomberg reported that the company was planning to raise over $60 billion in debt to fund a deal supporting Anthropic, the artificial intelligence company. The scale of the financing underscored how much money is flowing into AI infrastructure.
Not every stock moved higher. OSI Systems, which makes electronic systems and components, dropped almost 10% after fourth-quarter revenue came in at $484.1 million, below the $529.7 million analysts had expected. The company reported adjusted earnings of $3.78 per share, just barely missing the $3.77 estimate, but the revenue shortfall was the real problem. Guidance for the fiscal year ending in June 2027 also disappointed. Boston Beer, the maker of Twisted Tea, fell 3% after announcing that Chief Financial Officer Diego Reynoso would depart on September 14 to become finance chief at Ingredion.
There were winners in the less obvious places. O-I Glass, which manufactures glass containers, jumped 10% after Citi upgraded the stock to buy from neutral and raised its price target to $9 from $8—implying 41% upside from Thursday's close. InnovAge, a senior care services provider, gained 2% after KeyBanc upgraded shares to overweight, with analyst Matthew Gillmor writing that the company's turnaround appeared complete but significant operational optimization opportunities remained. Parsons, a technology provider focused on national security work, jumped 4% after Baird lifted its price target to $57 from $48 and upgraded the stock to outperform, suggesting about 24% upside ahead.
Bemerkenswerte Zitate
We believe INNV's turnaround is complete, yet there remain significant opportunities to optimize operations and accelerate growth.— Matthew Gillmor, KeyBanc analyst, on InnovAge
Möchten Sie die ganze Geschichte?
Das Original lesen bei CNBC ↗
Business